AbbVie Inc. is reportedly on the verge of acquiring Apogee Therapeutics Inc. for nearly $11 billion. This all-cash deal is intended to strengthen AbbVie's anti-inflammatory drug pipeline, a key area for the pharmaceutical giant. According to a Financial Times report, this acquisition signifies AbbVie's commitment to reinforcing its market position in immunology, especially following the patent expiration and biosimilar erosion of its blockbuster drug Humira.
The proposed acquisition price of around $10.9 billion reflects a substantial premium of approximately 60% over Apogee's closing share price of $90.38 on the Thursday prior to the announcement. This high premium indicates AbbVie's aggressive strategy to secure promising assets in the competitive biotech landscape. The deal, which could be announced as early as Monday, represents AbbVie's largest bolt-on acquisition since 2020.
Apogee Therapeutics is a clinical-stage biotech company specializing in antibody drugs for inflammatory and immune diseases. Its lead candidate, zumilokibart, is a long-acting alternative to Dupixent, a prominent inflammatory treatment. Zumilokibart is being developed as an injection administered every three to six months, offering a potential advantage over existing treatments that require more frequent dosing. This could significantly widen its application across conditions like atopic dermatitis, asthma, and other inflammatory conditions, positioning it to compete in the $200 billion global market if Phase 3 results are positive.
